Search results for "Amphotericin"

showing 10 items of 68 documents

Candida blood stream infections observed between 2011 and 2016 in a large Italian University Hospital: A time-based retrospective analysis on epidemi…

2019

Candida bloodstream infection (BSI) represents a growing infective problem frequently associated to biofilm production due to the utilization of intravascular devices. Candida species distribution (n = 612 strains), their biofilm production and hospital antifungal drug consumption were evaluated in different wards of a tertiary care academic hospital in Italy during the years 2011–2016. In the considered time window, an increasing number of Candida BSI (p = 0.005) and of biofilm producing strains were observed (p<0.0001). Although C. albicans was the species more frequently isolated in BSI with a major biofilm production, an increased involvement of non-albicans species was reported, partic…

0301 basic medicineAntifungal AgentsTime FactorsAntifungal drugYeast and Fungal ModelsPathology and Laboratory Medicinelaw.inventionHospitals Universitychemistry.chemical_compound0302 clinical medicinelawAmphotericin BMedicine and Health Sciences030212 general & internal medicineAmphotericinFluconazoleCandidaFungal PathogensPrincipal Component AnalysisMultidisciplinaryAntimicrobialsQCandidiasisREukaryotaDrugsIntensive care unitHospitalsCorpus albicansIntensive Care UnitsExperimental Organism SystemsItalyMedical MicrobiologyEngineering and TechnologyMedicinePathogensResearch ArticleBiotechnologymedicine.drugCandida Candida bloodstream infection biofilm antifungal agents drug susceptibilityCathetersScience030106 microbiologyBioengineeringMycologyMicrobial Sensitivity TestsResearch and Analysis MethodsMicrobiologyMicrobiology03 medical and health sciencesMicrobial ControlmedicineCandida AlbicansHumansMicrobial PathogensRetrospective StudiesPharmacologyVoriconazoleAntifungalsbusiness.industryOrganismsFungiBiofilmBiology and Life SciencesYeastHealth CarechemistryHealth Care FacilitiesBiofilmsAnimal StudiesMedical Devices and EquipmentAntimicrobial ResistanceCaspofunginbusinessFluconazolePLOS ONE
researchProduct

Candida thrombophlebitis in children: a systematic review of the literature

2020

Abstract Objective To describe a case of thrombophlebitis associated with Candida infection and to analyze other published reports to define clinical characteristics, prognostic data, diagnostic and therapeutic strategies. Study design A computerized search was performed without language restriction using PubMed and Scopus databases. An article was considered eligible for inclusion if it reported cases with Candida thrombophlebitis. Our case was also included in the analysis. Results A total of 16 articles reporting 27 cases of Candida thrombophlebitis were included in our review. The median age of patients was 4 years. In 10 cases there was a thrombophlebitis of peripheral veins; in the re…

0301 basic medicineAntifungal Agentsmedicine.medical_treatmentReviewThrombophlebitislaw.invention0302 clinical medicineRisk FactorslawAmphotericin BThrombosis.030212 general & internal medicineChildPersistent feverAntifungal therapyChildrenCandidaHospital-acquired infectionsCross InfectionAnticoagulantCandidiasislcsh:RJ1-570PrognosisIntensive care unitThrombosisChild PreschoolCentral venous cathetermedicine.drugmedicine.medical_specialtySepsimedicine.drug_class030106 microbiologySepsis03 medical and health sciencesAmphotericin BSepsisInternal medicinemedicineHumansEnoxaparinbusiness.industryAnticoagulantsThrombosislcsh:PediatricsThrombophlebitisNewbornmedicine.diseaseHospital-acquired infectionParenteral nutritionPhlebitisbusinessItalian Journal of Pediatrics
researchProduct

Time-kill assays of amphotericin B plus anidulafungin against Candida tropicalis biofilms formed on two different biomaterials.

2017

Purpose: To determine the fungicidal activity by time-killing assays of amphotericin B (AMB) combined with anidulafungin (ANF) against biofilms of 2 clinical isolates of Candida tropicalis and the reference strain ATCC® 750, developed on polytetrafluoroethylene (PTFE) and titanium, using the CDC Biofilm Reactor (CBR) as an in vitro model. Methods: Biofilms were developed for 24 hours on the disk surfaces and then exposed to AMB (40 mg/L), ANF (8 mg/L), alone and combined. At predetermined time points after drug exposure, biofilms were removed from the disk surface by vortexing-sonication to quantify viable biofilm cells. Results: Drug activity was dependent on strain and time. After exposur…

0301 basic medicineAntifungalmedicine.drug_class030106 microbiologyBiomedical EngineeringMedicine (miscellaneous)BioengineeringAnidulafunginMicrobiologyBiomaterialsCandida tropicalis03 medical and health sciencesAmphotericin BAmphotericin BmedicineCandida tropicalisTitaniumbiologyStrain (chemistry)ChemistryBiofilmBiomaterialGeneral Medicinebiology.organism_classificationBiofilmsAnidulafunginPTFEAntagonismmedicine.drugThe International journal of artificial organs
researchProduct

Good's syndrome and recurrent leishmaniasis: A case report and review of literature

2020

We report the case of a 56-year-old Caucasian male affected by thymoma and myasthenia gravis that developed recurrent visceral leishmaniasis 11 years after thymectomy. After treatment of each relapse with liposomal amphotericin B the PCR-Leishmania was negative and the patient showed clinical improvement. An immunologic work-up was performed showing lymphopenia with an important decrease in CD4+ T cells (52 cells/μ) and CD4/CD8 ratio (0.2). HIV test was negative. On the basis of previous thymoma and myasthenia gravis and on the basis of the immunological profile a diagnosis of Good's syndrome was made. Since IFNγ plays a main role in the control of Leishmania infection the production of IFN…

0301 basic medicineLeishmaniasiThymomamedicine.medical_treatmentT cellImmunologyLiposomal amphotericin BCase ReportGood's syndromeCD4+ T cell03 medical and health sciences0302 clinical medicinemedicineIntensive care medicinelcsh:Social sciences (General)lcsh:Science (General)LeishmaniasisInternal medicineInfectious diseaseMultidisciplinarybusiness.industryLeishmaniasisImmunotherapymedicine.diseaseLaboratory medicineCD4+ T cellsMyasthenia gravisThymectomy030104 developmental biologyVisceral leishmaniasismedicine.anatomical_structureImmunologylcsh:H1-99business030217 neurology & neurosurgeryCD8IFNγlcsh:Q1-390Heliyon
researchProduct

Direct-acting antivirals and visceral leishmaniasis: a case report

2019

Abstract Background Visceral leishmaniasis is a vector-borne parasitic disease caused by protozoa belonging to the genus Leishmania. The clinical presentation of visceral leishmaniasis strictly depends on the host immunocompetency, whereas depressive conditions of the immune system impair the capability to resolve the infection and allow reactivation from sites of latency of the parasite. Case presentation We describe a case of visceral leishmaniasis (VL) that occurred in a patient with chronic hepatitis C treated with direct-acting antiviral drugs (DAA). The hypothesized mechanism is the alteration of protective inflammation mechanisms secondary to DAA therapy. Downregulation of type II an…

0301 basic medicineMaleSofosbuvir030106 microbiologyAntiprotozoal AgentsCase ReportDirect-acting antiviralAntiviral Agentslcsh:Infectious and parasitic diseases03 medical and health scienceschemistry.chemical_compound0302 clinical medicineImmune systemAmphotericin BRibavirinHumansMedicinelcsh:RC109-216030212 general & internal medicineLeishmania infantumAgedAntiviral AgentLeishmaniaVisceral Leishmaniasisbiologybusiness.industryCoinfectionRibavirinHepatitis CHepatitis C Chronicbiology.organism_classificationmedicine.diseaseLeishmaniaHepatitis CInfectious DiseasesVisceral leishmaniasischemistryAntiprotozoal AgentImmunologyCoinfectionVisceral LeishmaniasiLeishmaniasis VisceralLeishmania infantumSofosbuvirbusinessmedicine.drugHumanBMC Infectious Diseases
researchProduct

In vitro activity of anidulafungin in combination with amphotericin B or voriconazole against biofilms of five Candida species

2016

Objectives: To evaluate the in vitro activity of anidulafungin combined with amphotericin B or voriconazole against Candida spp. biofilms. Methods: Four Candida albicans, four Candida tropicalis, four Candida glabrata, two Candida parapsilosis and two Candida orthopsilosis blood isolates were tested by the microdilution chequerboard method combined with the XTT metabolic assay. Biofilm MIC was defined as the lowest concentration producing 50% metabolic inhibition with respect to control (BMIC50). Concentrations in the combinations ranged from 1/8xBMIC(50) to 4xBMIC(50) found for each antifungal tested alone. Results: Anidulafungin plus amphotericin B acted synergistically against C. albican…

0301 basic medicineMicrobiology (medical)Antifungal Agents030106 microbiologyMicrobial Sensitivity TestsCandida parapsilosisAnidulafunginMicrobiologyCandida tropicalis03 medical and health sciencesEchinocandinsAmphotericin BAmphotericin BmedicineHumansPharmacology (medical)Candida albicansCandidaPharmacologyVoriconazolebiologyCandida glabrataChemistryCandidemiaDrug Synergismbiology.organism_classificationbacterial infections and mycosesCorpus albicansInfectious DiseasesBiofilmsAnidulafunginVoriconazolemedicine.drug
researchProduct

Characteristics and Management of Candidaemia Episodes in an Established Candida auris Outbreak

2020

The multi-resistant yeast Candida auris has become a global public health threat because of its ease to persist and spread in clinical environments, especially in intensive care units. One of the most severe manifestations of invasive candidiasis is candidaemia, whose epidemiology has evolved to more resistant non-albicansCandida species, such as C. auris. It is crucial to establish infection control policies in order to control an outbreak due to nosocomial pathogens, including the implementation of screening colonisation studies. We describe here our experience in managing a C. auris outbreak lasting more than two and a half years which, despite our efforts in establishing control measure…

0301 basic medicineMicrobiology (medical)medicine.medical_specialty<i>Candida auris</i>colonisation030106 microbiologymultidrug-resistantyeastBiochemistryMicrobiology03 medical and health sciences0302 clinical medicineInternal medicineIntensive careAmphotericin BEpidemiologyInfection controlMedicinecandidaemiaPharmacology (medical)030212 general & internal medicineGeneral Pharmacology Toxicology and Pharmaceuticsoutbreakbusiness.industryMortality ratelcsh:RM1-950Outbreaklcsh:Therapeutics. PharmacologyInfectious DiseasesCandida aurissurveillancefungibusinessFluconazolemedicine.drugAntibiotics
researchProduct

Imaging features of perineural and perivascular spread in rapidly progressive rhino-orbital-cerebral mucormycosis: A case report and brief review of …

2021

Background: Rhinocerebral mucormycosis (ROCM) is an opportunistic fungal infection originating from the paranasal sinuses with extension to the brain. A delayed diagnosis can rapidly result in a poor prognosis. ROCM commonly affects patients with diabetes or immunocompromised states with a variable progression. Case Description: We report the case of a 59-year old patient with an untreated diabetes who developed a ROCM with rapidly progressive neurological symptoms. From the onset of sinus pain, nasal congestion, he rapidly developed facial swelling and masticatory dysfunction. The patient underwent sinus surgery which allowed Rhizopus oryzae to be isolated. Accordingly, a systemic therapy…

0301 basic medicinemedicine.medical_specialtyPerivascular spread030106 microbiologyCase ReportNasal congestionMucormycosi03 medical and health sciences0302 clinical medicineZygomycosisPerineural spreadAmphotericin BDiabetes mellitusOcclusionmedicineMucormycosisbusiness.industryMucormycosisRhinocerebral mucormycosimedicine.diseaseThrombosisSurgeryParanasal sinusesmedicine.anatomical_structureRhinocerebral mucormycosisSurgeryMucormycosis; Perineural spread; Perivascular spread; Rhinocerebral mucormycosis; ZygomycosisNeurology (clinical)Zygomycosismedicine.symptombusiness030217 neurology & neurosurgerymedicine.drug
researchProduct

Prophylaxis of invasive fungal infections in patients with hematological malignancies and solid tumors

2003

Morbidity and mortality in patients with malignancies, especially leukemia and lymphoma, are increased by invasive fungal infections. Since diagnosis of invasive fungal infection is often delayed, antifungal prophylaxis is an attractive approach for patients expecting prolonged neutropenia. Antifungal prophylaxis has obviously attracted much interest resulting in dozens of clinical trials since the late 1970s. The non-absorbable polyenes are probably ineffective in preventing invasive fungal infections, but may reduce superficial mycoses. Intravenous amphotericin B and the newer azoles were used in clinical trials, but their role in antifungal prophylaxis is still not well defined. Allogene…

0303 health sciencesmedicine.medical_specialty030306 microbiologybusiness.industryOpportunistic infectionItraconazoleHematologyGeneral MedicineNeutropeniamedicine.disease3. Good healthClinical trial03 medical and health sciences0302 clinical medicineAmphotericin BChemoprophylaxisImmunologyMedicine030212 general & internal medicinebusinessIntensive care medicineMycosisFluconazolemedicine.drugAnnals of Hematology
researchProduct

Treatment outcome of invasive mould disease after sequential exposure to azoles and liposomal amphotericin B

2009

Objectives To analyse the potential antagonism between azoles, which inhibit ergosterol synthesis, and polyenes, which bind directly to ergosterol in cell membranes, in patients receiving sequential azole-polyene treatment. Methods In an earlier randomized, double blind study of liposomal amphotericin as initial therapy for invasive filamentous fungal infection (IFFI), a 3 mg/kg/day dose had a favourable overall response rate of 50% and 12 week survival rate of 72%. No improved outcome was seen with 10 mg/kg/day for the first 14 days. The study population was further analysed for the effect of prior azole exposure on treatment responses to liposomal amphotericin B. The protocol allowed prio…

AdultAzolesMaleMicrobiology (medical)medicine.medical_specialtyAntifungal AgentsAdolescentmedicine.drug_classAntibioticsPharmacologyAspergillosisGastroenterologyYoung AdultPharmacotherapyDouble-Blind MethodAmphotericin BInternal medicineAmphotericin BmedicineHumansDrug InteractionsPharmacology (medical)ChildSurvival rateMycosisAgedPharmacologyVoriconazolechemistry.chemical_classificationbusiness.industryInfantMiddle Agedmedicine.diseaseTreatment OutcomeInfectious DiseasesMycoseschemistryChild PreschoolAzoleFemalebusinessmedicine.drugJournal of Antimicrobial Chemotherapy
researchProduct